Until now, the pathologic and immunologic consequences of adding the CTLA-4 checkpoint inhibitor Ipi to neoadjuvant combined Nivo+CT for patients with resectable NSCLC have not been investigated. Here, CTLA4 is linked to non-small cell lung carcinoma.